Because of its (now) known feature, the SARSr-Cov-WIV's illness is readily resolved with early treatment that inhibits the viral replication that spreads the spike proteins around body (which induces a harmful overactive immune responses as the body tries to clear the spikes from the ACE2 receptors). Many of the early treatment protocols ignored by the authorities work because they inhibit viral replication or modulate the immune response to the spike proteins, which makes sense within the context of what ECoHealth was creating. Some of these treatment protocols also inhibit the action of the engineered spike proteins. For instance, Ivermectin (identified a curative in April 2020) works throughout all phases of illness because it both inhibits viral replications and modulates the immune response. Of notes, chloroquine phosphate (Hydroxychloroquine, identified April 2020 as curative) is identified in the proposal as SARSr-Cov inhibitor, as is interferon ( identified May 2020 as curative).